Rinvoq — Medica
juvenile idiopathic arthritis (JIA)
Initial criteria
- age ≥ 2 years
- Patient meets ONE of the following: a) 3‑month trial of at least one tumor necrosis factor inhibitor; OR b) unable to tolerate a 3‑month trial of at least one tumor necrosis factor inhibitor
- Medication prescribed by or in consultation with a rheumatologist
Reauthorization criteria
- Patient has been established on therapy for at least 6 months
- Patient meets ONE of the following: a) beneficial clinical response from baseline by objective measure (e.g., MD global, PGA, PDA, JDAS, cJDAS, JSpADA, CRP, ESR, or reduced corticosteroid dosage); OR b) improvement from baseline in at least one symptom such as improved motion, less joint pain or tenderness, decreased morning stiffness or fatigue, improved function or activities of daily living
Approval duration
initial 6 months; reauth 1 year